Cardioneuroablation is one of the emerging therapies in vasovagal syncope. In this study, we present a simple method of cardioneuroablation performed via a right-sided approach, targeting anterior-right and right-inferior ganglionated plexi, along with procedural and follow-up data. Patients who had underwent cardioneuroablation between March 2018 and September 2019 with vasovagal syncope in 2 clinics were enrolled in the study. All patients underwent radio-anatomically guided radiofrequency ablation targeting anterior-right ganglionated plexi and right-inferior ganglionated plexi. Syncope and symptom burden, 24-hour ambulatory electrocardiogram data at presentation, and at follow-up were assessed along with procedural data. A total of 23 patients underwent modified right-sided cardioneuroablation. Mean basal cycle length decreased significantly from 862.3 ± 174.5 ms at the beginning of the procedure 695.8 ± 152.1 ms following the final radiofrequency ablation (P < .001). Mean 24-hour ambulatory heart rate increased significantly from 66.4 ± 10.7 bpm at baseline to 80 ± 7.6 bpm at follow-up (P < .001). Only 1 patient had 1 episode of syncope following the procedure at the mean follow-up period of 10 ± 2.9 months. The same patient had recurrent presyncope. The right-sided cardioneuroablation approach was found to be an effective treatment for vasovagal syncope and may be regarded as a default initial cardioneuroablation technique.

Introduction: Acute heart failure (AHF) is associated with a dismal prognosis that is even poorer than the majority of cancer types. Therefore, clinical indicators that can aid in determining the prognosis of heart failure are of interest. Multiple risk prediction tools with varying sensitivity and specificities have been introduced before. In the current study, we aimed to evaluate whether the HALP score could accurately predict in‐hospital mortality in patients with AHF.Methods: We evaluated the medical records of a total of 153 patients admitted to our institution between August 2016–May 2018 for acute heart failure. The patients were divided into two groups: Group 1 (patients who died during hospital admission) and Group 2 (patients who were discharged from the hospital). The HALP score was calculated as: hemoglobin (g/L) x albumin (g/L) x lymphocytes (/L)/platelets (/L) for each patient. The two groups were compared in terms of HALP scores. The receiver operator characteristic (ROC) curve was utilized to assess the predictive performance of HALP on in‐hospital mortality in AHF.Results: Patients who died during admission had lower HALP scores compared with the patients who were discharged uneventfully. A ROC curve analysis was performed to predict the optimal cut‐off value of the HALP score. The area under the curve (AUC), sensitivity, specificity, and the cut‐off value were 0.650, 43%, 57%, 21,5 respectively (p = 0.014).Conclusion: Despite all evolving treatment modalities, heart failure‐related mortality rates remain high. Prompt recognition of patients with an unfavorable prognosis is vital for the timely implementation of disease‐modifying therapeutic interventions. The HALP score, being a readily calculable tool, serves as an effective means to pinpoint individuals at a heightened risk of in‐hospital mortality. We believe that the HALP score holds promise as a practical tool for predicting in‐mortality among patients admitted for AHF.

COVID-19,echocardiography,2-dimensional speckle tracking imaging